Chiesi Ready To Reap Benefits Of Rare Disease Expansion
Amryt Buy Will Boost 2023 Sales
The Italian drugmaker has reported strong sales for 2022 driven by its respiratory drugs but this year will see a more prominent contribution from its rare disease offerings.
